Company Overview
Klotho Neurosciences Inc is a biotechnology enterprise dedicated to the development of therapeutic medicines designed to treat cancer, cardiovascular disorders, and neurodegenerative conditions. The company operates within the broader Healthcare sector, specifically focusing on the specialized industry of Biotechnology where innovation in gene therapy and drug discovery is central to its operational model. According to available data, the company maintains a market capitalization of $56.66M and employs a workforce of 3 individuals, while reported annual revenue figures are not currently available for public disclosure. This combination of a mid-single digit market cap and minimal employee count indicates that Klotho Neurosciences is an early-stage or late-stage clinical entity with limited commercial scale, suggesting that its current valuation is driven primarily by pipeline potential and intellectual property rather than established cash-generating operations.
Financial Health
The company reports a net income loss of $-11,290,061 over the trailing twelve months, while revenue and EBITDA figures are not available, creating a financial picture where the gap between potential revenue and actual net loss highlights a cost structure heavily weighted toward research and development expenses typical of biotechnology firms. Free cash flow stands at $-5,885,180, which signifies that the company is currently burning cash to fund its operations and clinical trials, thereby limiting immediate financial flexibility without access to additional capital markets or existing reserves. All three key profitability metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that reflects the pre-revenue or pre-profit nature of the business where costs exceed any generated income before taxes. In terms of liquidity and leverage, the company holds $7.35M in cash with no recorded debt and a debt-to-equity ratio listed as not available, indicating a conservative balance sheet that is debt-free but reliant on cash reserves to sustain operations. The current ratio is 83.69, an exceptionally high figure that suggests the company possesses ample short-term assets relative to its liabilities, providing a robust buffer against immediate liquidity pressures despite the negative cash flow. Furthermore, the return on equity is -198.3% and the return on assets is -71.6%, metrics that reveal that management is currently generating negative returns on the capital invested, which is characteristic of biotechnology companies in the development phase but indicates that profitability has not yet been achieved.
Valuation Assessment
Trailing P/E and forward P/E ratios are both not available due to the absence of earnings, meaning the difference between them cannot be analyzed in the context of expected earnings trajectory. The price-to-book ratio is 3.72, which indicates that the market is valuing the company at a significant premium relative to its net asset value, likely attributing high value to the unrecorded intangible assets such as clinical trial data and patent portfolios. Price-to-sales and EV/EBITDA metrics are not available, suggesting that these alternative valuation methods are currently inapplicable or irrelevant for this specific asset given its lack of sales and earnings. The 52-week high is $3.91 and the 52-week low is $0.11, placing the current trading position within a highly volatile range that spans nearly forty times the lowest price point observed in the last year. The beta value is 2.23, which implies that the stock price exhibits more than double the volatility of the broader market, exposing investors to significantly higher price swings during periods of market turbulence.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available, preventing a direct comparison of whether earnings are growing faster or slower than revenue. Since the company does not pay dividends, the dividend yield is not available and the payout ratio is 0.0%, indicating that the company reinvests all available resources back into research, development, and operational growth rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current earnings generation or dividend distribution, relying entirely on future clinical successes to transition into a profitable growth phase.